抗痨颗粒辅助治疗难治性肺结核的临床效果及安全性探析  

Analysis of clinical effect and safety of anti-tuberculosis granule in adjuvant treatment of refractory pulmonary tuberculosis

作　　者：唐蒙轩 沈莉华 TANG Meng-xuan;SHEN Li-hua(Department of Pharmacy,Yuebei Second People＇ s Hospital,Shaoguan 512026,China)

机构地区：[1]粤北第二人民医院药剂科,512026

出　　处：《中国现代药物应用》2018年第12期76-77,共2页Chinese Journal of Modern Drug Application

摘　　要：目的探讨抗痨颗粒辅助治疗难治性肺结核的临床效果及安全性。方法 66例难治性肺结核住院患者,根据住院先后顺序分为观察组与对照组,各33例。两组均给予3HRZE/6HR抗结核治疗,观察组在此基础上给予抗痨颗粒辅助治疗。比较两组患者治疗开始后第1、3、6个月痰菌转阴率,治疗效果及不良反应发生情况。结果观察组治疗开始后第1、3、6个月痰菌转阴率均明显高于对照组,差异具有统计学意义(P<0.05)。观察组治疗总有效率为93.94%,明显高于对照组的72.73%,差异有统计学意义(P<0.05)。两组均未发现严重不良反应,两组不良反应发生率比较差异无统计学意义(P>0.05)。结论抗痨颗粒辅助治疗难治性肺结核具有起效快、疗效显著、安全性高的特点,是一种理想的辅助治疗药物。Objective To investigate the clinical effect and safety of anti-tuberculosis granule in adjuvant treatment of refractory pulmonary tuberculosis. Methods A total of 66 patients with refractory pulmonary tuberculosis were divided by admission order into observation group and control group, with 33 cases in each group. Both groups received 3 HRZE/6 HR anti tuberculosis treatment, and the observation group also received anti-tuberculosis granule. Comparison were made on sputum negative-conversion rate after 1 month, 3 and 6 months of treatment, treatment effect and occurrence of adverse reactions between the two groups. Results The observation group had obviously higher sputum negative-conversion rate after 1 month, 3 and 6 months of treatment than the control group, and the differences were statistically significant（P〈0.05）. The observation group had obviously higher total treatment effective rate as 93.94% than 72.73% in the control group, and the difference was statistically significant（P〈0.05）. No serious adverse reactions were found in the two groups. There was no significant difference in the incidence of adverse reactions between the two groups（P〉0.05）. Conclusion Antituberculosis granule adjuvant therapy for refractory pulmonary tuberculosis has the characteristics of rapid onset, significant efficacy, and high safety, and it is an ideal adjuvant therapy drug.

关 键 词：难治性肺结核 抗痨颗粒 治疗效果 

分 类 号：R521[医药卫生—内科学]